A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition toeltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response orrelapsed after first line steroid treatment (VAYHIT2

Project: Research project

Project Details

Description

A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first line steroid treatment (VAYHIT2
StatusActive
Effective start/end date3/27/24 → 3/31/34

Funding

  • NOVARTIS PHARMACEUTICALS CORPORATION

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint